Stockreport

Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference [Yahoo! Finance]

Arcutis Biotherapeutics, Inc. - Common stock  (ARQT) 
PDF Preclinical data on ARQ-234, CD200R agonist, for the treatment of atopic dermatitis Additional presentation of the consistent tolerability profile of topical roflumil [Read more]